SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-56853"
 

Sökning: id:"swepub:oai:DiVA.org:oru-56853" > Changes of cerebros...

Changes of cerebrospinal fluid cytokine profile as a result of switching from first line MS-therapies to rituximab

de Flon, P. (författare)
Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden
Söderström, L. (författare)
Unit of Research, Education and Development, Region Jämtland Härjedalen, Östersund, Sweden
Laurell, K. (författare)
Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden
visa fler...
Gunnarsson, Martin, 1973- (författare)
Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Neurology and Neurophysiology, Örebro University Hospital, Örebro, Sweden
Svenningsson, A. (författare)
Department of Clinical Sciences, Karolinska Institute, Stockholm, Sweden
visa färre...
 (creator_code:org_t)
Sage Publications, 2016
2016
Engelska.
Ingår i: Multiple Sclerosis Journal. - : Sage Publications. - 1352-4585 .- 1477-0970. ; 22:Suppl. 3, s. 622-622
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: New treatment strategies in multiple sclerosis provide insights not only in the clinical effects but also, by their differences in mechanisms of action, in the immunopathological mechanisms behind disease activity.Objective: This study describes the change in cyto- and chemokine profile over a two-year period in a cohort of patients with clinically stable RRMS after treatment shift from ongoing first-line injectable disease modifying therapy (iDMT), e.g. interferon beta or glatirameracetat, to the anti-CD20 depleting agent rituximab and the differences compared with a cohort of healthy controls.Method: CSF from 73 patients with clinically stable RRMS was analysed by an elektrochemiluminiscens-based ELISA for a panel of 22 cytokines before and one and two year after treatment shift to rituximab and compared with 55 healthy controls.Results: During the first year of treatment it was a significant reduction (p< 0.005) in levels of IL-6, IL-8, IL-10, IL-12, IL-15, IP-10, MCP-1, MDC, TARC, sICAM, sVCAM and a significant elevation (p< 0,005) in levels of IL-7 and MIP-1b.Compared to healthy controls it was a significantly higher (p< 0,005) level of IFN-gamma, IL-6, IL-8, IL-10, IL-12, IL-15, TNF, IP-10, MDC, MIP-1a, MIP-1b, TARC, SAA, sICAM and sVCAM in patients with RRMS before treatment shift. Levels of IL-5 and IL-7 were significantly lower. One year after treatment shift the levels of IFN-gamma, IL-6, IL-7, IL-15, MIP-1a and SAA did not differ significantly between patients with RRMS and healthy controls.Conclusion: This study demonstrates significant changes in cyto- and chemokine profile in patients with RRMS after treatment shift from iDMT to rituximab and compared with healthy controls.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
de Flon, P.
Söderström, L.
Laurell, K.
Gunnarsson, Mart ...
Svenningsson, A.
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
och Neurologi
Artiklar i publikationen
Multiple Scleros ...
Av lärosätet
Örebro universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy